Insights and Innovations: A Review of the GRAPPA 2023 Trainee Symposium

M.E. Husni, MD, MPH, S. Cheemalavagu, MD, Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, Ohio, USA.
A.W. Armstrong, MD, MPH, Department of Dermatology, University of California Los Angeles, Los Angeles, California, USA.
L. Eder, MD, PhD, Women's College Hospital, University of Toronto, Toronto, Ontario, Canada.

As part of the supplement series GRAPPA 2023, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards.
MEH has served on the National Psoriasis Foundation Board of Directors and as a research investigator and/or scientific adviser/consultant to AbbVie, Amgen, Novartis, Lilly, Pfizer, UCB, and Janssen. AWA has served as a research investigator, scientific adviser, and/or speaker to AbbVie, Almirall, Arcutis, ASLAN, Beiersdorf, BI, BMS, EPI, Incyte, Leo, UCB, Janssen, Lilly, Mindera, Nimbus, Novartis, Ortho Dermatologics, Sun, Dermavant, Dermira, Sanofi, Regeneron, and Pfizer. LE received research and educational grants from AbbVie, Pfizer, Janssen, Novartis, Eli Lilly, Sandoz, and Fresenius Kabi. SC declares no conflicts of interest relevant to this article.
This paper does not require institutional review board approval.
Accepted for publication March 10, 2024.